Medexus Pharmaceuticals Inc (MDP) - Total Assets
Based on the latest financial reports, Medexus Pharmaceuticals Inc (MDP) holds total assets worth CA$154.98 Million CAD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medexus Pharmaceuticals Inc - Total Assets Trend (2012–2025)
This chart illustrates how Medexus Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Medexus Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (March 2025)
Medexus Pharmaceuticals Inc's total assets of CA$154.98 Million consist of 46.9% current assets and 53.1% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$23.97 Million | 14.0% |
| Accounts Receivable | CA$13.31 Million | 7.7% |
| Inventory | CA$35.29 Million | 20.5% |
| Property, Plant & Equipment | CA$689.00K | 0.4% |
| Intangible Assets | CA$71.60 Million | 41.7% |
| Goodwill | CA$10.00 Million | 5.8% |
Asset Composition Trend (2012–2025)
This chart illustrates how Medexus Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medexus Pharmaceuticals Inc's current assets represent 46.9% of total assets in 2025, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 14.0% of total assets in 2025, down from 83.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 41.7% of total assets.
Medexus Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Medexus Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩642.17 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp Preferred
KO:000105
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Yuyu Pharma
KO:000220
|
Korea | ₩202.42 Billion |
|
Ildong Holdings Co Ltd
KO:000230
|
Korea | ₩813.62 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Medexus Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.12 | 1.01 | 1.47 |
| Quick Ratio | 0.62 | 0.49 | 1.10 |
| Cash Ratio | 0.24 | 0.13 | 0.00 |
| Working Capital | CA$7.57 Million | CA$368.00K | CA$18.63 Million |
Medexus Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Medexus Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.38 |
| Latest Market Cap to Assets Ratio | 0.54 |
| Asset Growth Rate (YoY) | 10.3% |
| Total Assets | CA$171.84 Million |
| Market Capitalization | $92.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medexus Pharmaceuticals Inc's assets below their book value (0.54x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Medexus Pharmaceuticals Inc's assets grew by 10.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Medexus Pharmaceuticals Inc (2012–2025)
The table below shows the annual total assets of Medexus Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | CA$171.84 Million | +10.34% |
| 2024-03-31 | CA$155.73 Million | -3.47% |
| 2023-03-31 | CA$161.33 Million | +15.88% |
| 2022-03-31 | CA$139.22 Million | -6.25% |
| 2021-03-31 | CA$148.51 Million | +20.93% |
| 2020-03-31 | CA$122.81 Million | +43.25% |
| 2019-03-31 | CA$85.73 Million | +1095.94% |
| 2018-03-31 | CA$7.17 Million | +23.71% |
| 2017-03-31 | CA$5.79 Million | -1.72% |
| 2016-03-31 | CA$5.90 Million | -17.61% |
| 2015-03-31 | CA$7.16 Million | -16.76% |
| 2014-03-31 | CA$8.60 Million | +401.34% |
| 2013-03-31 | CA$1.71 Million | +291.39% |
| 2012-03-31 | CA$438.15K | -- |
About Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of… Read more